think re-affirmed guidanc ex-tax reform prove conserv given strong
underli fundament pharma better expect perform patient
recoveri compens issu cordi exam glove also
concern potenti threat medic see near-term
issu although difficult say long-term
fundament pharma appear stabil upsid guid
quarter commentari suggest fundament pharma stabil
result pharma came better consensu management expect notabl gener
sell-sid price in-lin management expect mid-singl digit deflat red
oak perform better expect like driver out-performance
quarter brand inflat also in-lin management expect furthermor
specialti grew double-digit top- bottom-lin basi given appear
strong underli fundament think pharma like continu outperform
remaind fiscal year despit management re-affirmed pharma guidanc
better expect perform patient recoveri bode medic
think quarter better expect result medic indic may
revert back consist perform miss expect previou three
quarter result driven perform recent acquir patient
strong double-digit profit growth versu prior year despit downward revis
segment profit exclud patient recoveri busi flat solid
growth due cordi exam glove impli patient recoveri busi
perform ahead manag initi expect think cordi
exam glove busi recov near-term medic could outperform guidanc
signific threat medic near-term
threat cover john blackledg pharma busi subsid
wsj articl regard push medic distribut hospit weigh
share recent although difficult determin success
ventur long-term think consider barrier entri exist
short-term given complex servic hospit recal recent confer
call make sens amazon enter drug distribut decemb expert
note distributor provid addit servic charg back rebat
behalf manufactur administ agre upon price hospit
manufactur also larg shipment size servic hospit requir truckload
oppos packag even hold discuss hospit
found difficult get hospit administr turn suppli chain
addit even wsj articl note reluct hospit use
cite concern regard lack option lack control purchas ship
well concern regard continu lack assur product
avail deliv secur medic suppli distribut current provid
pleas see page report import disclosur
believ medic strategi benefit recent
acquisit patient recoveri busi cautiou well
distributor see challeng pharma segment challeng includ price
pressur gener well diminish contribut gener introduct
gener wave come end said believ stabil gener price could
allow higher growth profil medic segment flow bottom-lin
coupl capit deploy could lead toward normal growth
 addit details/progress red oak
 progress medic
 at-risk gener inflat
brand gener
 progress specialti
 integr acquisit
 gross margin pressur
 ebit margin
 top-lin growth high-singl digit
due better-than-expect contribut
gener
 gross margin closer greater
benefit red oak medic
 sg come better oper
 share repo greater
 top-lin growth low-single-digit due
weaker-than-expect contribut
 gross margin weaker-
than-expect pressur gener
 restructur cost weigh
one three largest pharmaceut distribut compani
 oper billion pharmaceut market compani distribut
comprehens offer brand-nam gener pharmaceut over-the-count
healthcar product home healthcar suppli equip wide varieti
healthcar provid locat throughout includ acut care hospit health
system independ chain retail pharmaci mail-ord facil physician clinic
alternate-sit facil cardin oper today two report segment
pharmaceut medic cardin recent focus home health space
updat estim price
rais adj ep estim
respect rais price target base revis dcf
analysi impli share trade adj ep estim
current multipl
compani file cowen compani
changevariancetot good gross gross bp chang gener oper oper interest pre-tax pre-tax incom tax net incom continu net incom deal-rel discontinu operations- nm- non-recurring net incom weight averag continu ep deal-rel ep non-recurring ex-disc ep oper oper bp chang medic oper oper bp chang cowen
million except per share data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end june cowen
million except per share data
compani file cowen compani
good gross gross chang sell gener oper interest pre-tax incom tax incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag ep continu ep chang year-over-year oper incom continu continu year end june cowen
million except per share data
compani file cowen compani
good gross gross chang sell gener oper interest pre-tax pre-tax incom tax net earn attribut non-controlling net incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag adj chang year-over-year oper incom continu continu cowen
million
compani file cowen compani
y/i total y/i total oper chang medic y/i total y/i total oper chang y/i revenu includ corpor report revenu includ corporo difference- report revenu oper cowen
million
compani file cowen compani
asset trade receiv merchandis prepaid expens current pp goodwil total current liabil current portion long-term account accru current long-term defer tax redeem non-controlling interest- stockhold equiti common retain common share cumul foreign currenc non-controlling interests- total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end june cowen
million
compani file cowen compani
income/ loss cumul effect chang accounting- earn /loss discontinu operations- earn cont op b/f effect chg flow oper activ depreci sale provis loss account charg reorg busi charges- sale invest businesses- employe stock defer incom invest impair chang oper asset liabil account merchandis prepaid expens assets- account oper net cash use /provid op activ disc ops- net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend common proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur year end june cowen
million
compani file cowen compani
flow oper activitiesnet cumul effect chang accounting- earn /loss discontinu earn cont op cumul effect chang adjust reconcil net earn net cash depreci sale investments- asset loss debt extinguishment- sale carefus common stock- purchas in-process d- equiti provis defer incom tax provis bad debt chang fair valu conting consider oblig chang oper asset liabil net increas trade receiv increas increas net invest sales-typ leases- increas account oper item net net cash use /provid oper activ discontinu ops- net cash provid oper flow invest activ acquisition/divestitur subsidiari net cash acquir proce sale properti equip addit properti equip sale/ purchas market secur avail sale proce matur available-for-sal securities- proce divestitur dispos held sale assets- proce sale carefus common stock- net cash use /provid invest activ discontinu ops- net cash use invest flow financ activ payment conting consideration- net chang commerci paper short-term debt reduct long-term oblig net purchas non-controlling interests- proce interest rate swap terminations- proce long-term oblig net issuanc cost proce securit borrow payment premium debt extinguishment- proce issuanc common share tax benefit exercis stock purchas treasuri share net cash use /provid financ activ discontinu ops- net cash provid by/ use financ effect exchang rate chang cash equivalents- net increas decreas chang fiscal year equival begin equival end fiscal year end june cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ
abil turnaround medic segment integr risk relat cordi harvard
drug group manag abil deploy capit effect
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
